Filing Details

Accession Number:
0001179110-20-001412
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-10 19:22:24
Reporting Period:
2020-02-07
Accepted Time:
2020-02-10 19:22:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
896264 Usana Health Sciences Inc USNA Medicinal Chemicals & Botanical Products (2833) 870500306
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1565541 A. Paul Jones 3838 West Parkway Blvd.
Salt Lake City UT 84120
Chief Leadership Dev Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-07 3,635 $70.75 8,669 No 4 M Direct
Common Stock Disposition 2020-02-07 3,635 $80.50 5,034 No 4 S Direct
Common Stock Acquisiton 2020-02-07 533 $70.75 5,567 No 4 M Direct
Common Stock Disposition 2020-02-07 533 $81.00 5,034 No 4 S Direct
Common Stock Acquisiton 2020-02-10 3,265 $70.75 8,299 No 4 M Direct
Common Stock Disposition 2020-02-10 3,265 $81.00 5,034 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock - Settles Stock Appreciation Right Disposition 2020-02-07 30,000 $0.00 30,000 $70.75
Common Stock Stock - Settles Stock Appreciation Right Disposition 2020-02-07 4,210 $0.00 4,210 $70.75
Common Stock Stock - Settles Stock Appreciation Right Disposition 2020-02-10 25,790 $0.00 25,790 $70.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,000 2018-09-01 2020-03-01 No 4 M Direct
25,790 2019-09-01 2020-03-01 No 4 M Direct
0 2019-09-01 2020-03-01 No 4 M Direct
Footnotes
  1. The shares acquired resulted from the reporting person's settlement of the stock-settled stock appreciation rights disclosed in Table II.